RAPIDe-3 Study Design and Demographics - The RAPIDe-3 study was a double-blind crossover trial evaluating deucrictibant IR 20 mg versus placebo for HAE attacks[17] - The efficacy analyses were based on 88 paired attacks[19] - The study enrolled 134 participants, including 10 adolescents (7.5%) and 124 adults (92.5%)[20] - The median age of participants was 38 years, and 56.7% were female[23] Efficacy Endpoints - Deucrictibant significantly reduced the time to onset of symptom relief to 1.28 hours compared to placebo (p < 0.0001)[35] - Deucrictibant significantly reduced the time to End of Progression (EoP) to 17.47 minutes compared to placebo (p < 0.0001)[38] - Deucrictibant significantly reduced the time to substantial symptom relief by PGI-C to 2.85 hours compared to placebo (p < 0.0001)[42] - Deucrictibant significantly reduced the time to substantial symptom relief by PGI-S to 2.41 hours compared to placebo (p < 0.0001)[47] - Deucrictibant significantly reduced the time to complete symptom resolution to 11.95 hours compared to placebo (p < 0.0001)[51] Treatment and Safety - 83% of attacks were treated with a single capsule of deucrictibant[54] - 93.2% of attacks were treated without rescue medication with deucrictibant versus 63.6% with placebo[54]